Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2

Lloyd Paul Aiello; Louis Vignati; Matthew J Sheetz; Xin Zhi; Aniz Girach; Matthew D Davis; Anne M Wolka; Nazila Shahri; Roy C Milton; PKC-DRS and PKC-DRS2 Study Groups

doi:10.1097/IAE.0b013e3182111669

Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2

Lloyd Paul Aiello, Louis Vignati, Matthew J Sheetz, Xin Zhi, Aniz Girach, Matthew D Davis, Anne M Wolka, Nazila Shahri, Roy C Milton, PKC-DRS and PKC-DRS2 Study Groups

Afdeling for Øjensygdomme

94 Citationer (Scopus)

Abstract

To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very severe nonproliferative diabetic retinopathy from the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 ruboxistaurin (RBX) protein kinase C β inhibitor trials.

Originalsprog	Engelsk
Tidsskrift	Retina
Vol/bind	31
Udgave nummer	10
Sider (fra-til)	2084-94
Antal sider	11
ISSN	0275-004X
DOI	https://doi.org/10.1097/IAE.0b013e3182111669
Status	Udgivet - 2011

Adgang til dokumentet

10.1097/IAE.0b013e3182111669

Fingeraftryk

Dyk ned i forskningsemnerne om 'Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Aiello, L. P., Vignati, L., Sheetz, M. J., Zhi, X., Girach, A., Davis, M. D., Wolka, A. M., Shahri, N., Milton, R. C., & PKC-DRS and PKC-DRS2 Study Groups (2011). Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina, 31(10), 2084-94. https://doi.org/10.1097/IAE.0b013e3182111669

Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. / Aiello, Lloyd Paul; Vignati, Louis; Sheetz, Matthew J et al.
I: Retina, Bind 31, Nr. 10, 2011, s. 2084-94.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Aiello, LP, Vignati, L, Sheetz, MJ, Zhi, X, Girach, A, Davis, MD, Wolka, AM, Shahri, N, Milton, RC & PKC-DRS and PKC-DRS2 Study Groups 2011, 'Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2', Retina, bind 31, nr. 10, s. 2084-94. https://doi.org/10.1097/IAE.0b013e3182111669

Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD et al. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina. 2011;31(10):2084-94. doi: 10.1097/IAE.0b013e3182111669

Aiello, Lloyd Paul ; Vignati, Louis ; Sheetz, Matthew J et al. / Oral protein kinase c β inhibition using ruboxistaurin : efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. I: Retina. 2011 ; Bind 31, Nr. 10. s. 2084-94.

@article{f4cf07a273aa48d5829122526cb788f6,

title = "Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2",

abstract = "To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very severe nonproliferative diabetic retinopathy from the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 ruboxistaurin (RBX) protein kinase C β inhibitor trials.",

author = "Aiello, {Lloyd Paul} and Louis Vignati and Sheetz, {Matthew J} and Xin Zhi and Aniz Girach and Davis, {Matthew D} and Wolka, {Anne M} and Nazila Shahri and Milton, {Roy C} and {PKC-DRS and PKC-DRS2 Study Groups}",

year = "2011",

doi = "10.1097/IAE.0b013e3182111669",

language = "English",

volume = "31",

pages = "2084--94",

journal = "Retina",

issn = "0275-004X",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Oral protein kinase c β inhibition using ruboxistaurin

T2 - efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2

AU - Aiello, Lloyd Paul

AU - Vignati, Louis

AU - Sheetz, Matthew J

AU - Zhi, Xin

AU - Girach, Aniz

AU - Davis, Matthew D

AU - Wolka, Anne M

AU - Shahri, Nazila

AU - Milton, Roy C

AU - PKC-DRS and PKC-DRS2 Study Groups

PY - 2011

Y1 - 2011

N2 - To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very severe nonproliferative diabetic retinopathy from the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 ruboxistaurin (RBX) protein kinase C β inhibitor trials.

AB - To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very severe nonproliferative diabetic retinopathy from the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 ruboxistaurin (RBX) protein kinase C β inhibitor trials.

U2 - 10.1097/IAE.0b013e3182111669

DO - 10.1097/IAE.0b013e3182111669

M3 - Journal article

C2 - 21862954

SN - 0275-004X

VL - 31

SP - 2084

EP - 2094

JO - Retina

JF - Retina

IS - 10

ER -